- Umeclidinium Bromide
-
-
2026-06-03
- CAS:869113-09-7
- Min. Order: 1Kg/Bag
- Purity: 0.99
- Supply Ability: 20 tons
- Umeclidinium bromide
-
- $124.00
-
2026-05-15
- CAS:869113-09-7
- Min. Order: 1g
- Purity: 99
- Supply Ability: 100KG
|
| | Umeclidinium bromide Basic information |
| Product Name: | Umeclidinium bromide | | Synonyms: | DIPHENYL-[1-(2-PHENYLMETHOXYETHYL)-1-AZONIABICYCLO[2.2.2]OCTAN-4-YL]METHANOL;BROMIDE;CS-1562;Umeclidinium bromide(GSK573719A);GSK573719A;GSK-573719A;GSK 573719A;GSK573719A;UMeclidiniuM broMide;UMeclidiuM;UMeclidiniuM BroMide (API) | | CAS: | 869113-09-7 | | MF: | C29H34BrNO2 | | MW: | 508.48976 | | EINECS: | 638-761-1 | | Product Categories: | 869113-09-7;API | | Mol File: | 869113-09-7.mol |  |
| | Umeclidinium bromide Chemical Properties |
| Melting point | >231°C (dec.) | | storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | DMSO (Slightly), Methanol (Slightly), Water (Slightly) | | form | Solid | | color | White to Off-White | | Stability: | Hygroscopic | | InChI | InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1 | | InChIKey | PEJHHXHHNGORMP-UHFFFAOYSA-M | | SMILES | [N+]12(CCOCC3=CC=CC=C3)CCC(C(O)(C3=CC=CC=C3)C3=CC=CC=C3)(CC1)CC2.[Br-] |
| | Umeclidinium bromide Usage And Synthesis |
| Description | Umeclidinium bromide is a long-acting muscarinic acetylcholine
antagonist developed by GlaxoSmithKline and approved
by the US FDA at the end of 2013 for use in combination with
vilanterol, a b2 agonist, for the treatment of chronic obstructive
pulmonary disease. Due to umeclidinium’s poor oral bioavailability,
the drug is administrated by inhalation as dry powder. | | Uses | Umeclidinium Bromide is considered as a potentially long-acting antimuscarinic agent. | | Definition | ChEBI: A quaternary ammonium salt that is the bromide salt of umeclidinium. Used in combination with vilanterol for long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease. | | Synthesis | Commercially available ethyl isonipecotate (278) was alkylated
with 1-bromo-2-chloroethane in the presence of K2CO3 in acetone
to give ethyl 1-(2-chloroethyl)piperidine-4-carboxylate (279). This
material was then treated with lithium diisopropylamine (LDA) in
THF to affect a transannular substitution reaction resulting in the
cyclized quinuclidine 280 in 96% yield. Excess of phenyllithium
was added to ester 280 in THF starting at low temperature then
gradually warming to room temperature to give tertiary alcohol 281 in 61% yield. Amine 281 was finally alkylated with benzyl 2-
bromoethyl ether (282) in MeCN/CHCl3 at elevated temperatures
to afford umeclidinium bromide (XXXV) in 69% yield. 
| | references | [1] salmon m, luttmann m a, foley j j, et al. pharmacological characterization of gsk573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. journal of pharmacology and experimental therapeutics, 2013, 345(2): 260-270. |
| | Umeclidinium bromide Preparation Products And Raw materials |
|